Q3 Earnings Estimate for NeuroPace Issued By Leerink Partnrs

NeuroPace, Inc. (NASDAQ:NPCE) – Research analysts at Leerink Partnrs lowered their Q3 2025 earnings estimates for shares of NeuroPace in a research report issued to clients and investors on Wednesday, May 28th. Leerink Partnrs analyst M. Kratky now expects that the company will earn ($0.22) per share for the quarter, down from their previous forecast of ($0.21). The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for NeuroPace’s Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($0.52) EPS and FY2027 earnings at ($0.29) EPS.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.05. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The company had revenue of $22.52 million for the quarter, compared to analyst estimates of $21.85 million.

A number of other research analysts have also issued reports on the stock. HC Wainwright assumed coverage on shares of NeuroPace in a research note on Wednesday. They issued a “buy” rating and a $18.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $17.00 target price on shares of NeuroPace in a research note on Wednesday, May 14th. Finally, JPMorgan Chase & Co. raised their target price on shares of NeuroPace from $14.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, NeuroPace currently has an average rating of “Moderate Buy” and an average target price of $15.50.

NeuroPace Stock Performance

NASDAQ:NPCE opened at $12.98 on Friday. NeuroPace has a 1 year low of $5.45 and a 1 year high of $18.98. The firm’s fifty day simple moving average is $12.83 and its 200 day simple moving average is $12.18. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The firm has a market capitalization of $425.73 million, a PE ratio of -12.98 and a beta of 2.04.

Insider Buying and Selling at NeuroPace

In other NeuroPace news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $15.85, for a total value of $2,664,955.60. Following the completion of the sale, the insider now directly owns 3,238,199 shares of the company’s stock, valued at $51,325,454.15. This represents a 4.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 22.20% of the company’s stock.

Institutional Trading of NeuroPace

A number of hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers boosted its holdings in NeuroPace by 15.2% in the 1st quarter. Rhumbline Advisers now owns 17,227 shares of the company’s stock valued at $212,000 after purchasing an additional 2,267 shares during the period. Petrus Trust Company LTA acquired a new stake in shares of NeuroPace during the 1st quarter valued at about $165,000. First Light Asset Management LLC acquired a new stake in shares of NeuroPace during the 1st quarter valued at about $19,468,000. Birchview Capital LP boosted its position in shares of NeuroPace by 64.4% during the 1st quarter. Birchview Capital LP now owns 16,442 shares of the company’s stock valued at $202,000 after acquiring an additional 6,442 shares in the last quarter. Finally, Ghisallo Capital Management LLC acquired a new stake in shares of NeuroPace during the 1st quarter valued at about $2,458,000. 78.83% of the stock is owned by institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.